It has been shown that BCL-2 expression is significantly low for NASH patients (10,46), suggesting that the pathological progression of NASH was negatively correlated with BCL-2 expression level. The gene discussed is BCL2; the disease is metabolic dysfunction-associated steatohepatitis.